INTRODUCTION {#h0.0}
============

The global mortality due to invasive pneumococcal disease (IPD) has been estimated at more than 1 million per annum, with the majority of deaths occurring in children less than 5 years old ([@B1]). Use of a 7-valent pneumococcal conjugate vaccine (PCV7) and subsequent 13-valent (PCV13) formulations has been followed by a precipitate reduction in IPD due to vaccine serotypes (VTs) in the United States, including a substantial herd effect in unvaccinated individuals ([@B2], [@B3]). PCVs are plainly an effective selective pressure on the pneumococcal population. The response to that pressure has been notable for the increase in prevalence of nonvaccine serotypes (NVTs). More than 90 distinct serotypes have been described ([@B4][@B5][@B5][@B6][@B7][@B8][@B9][@B10]), so even PCV13 protects against a small minority of antigenic diversity in this organism. Following vaccination, the prevalence of NVTs in carriage, and to a lesser extent in IPD, has increased as the NVTs took advantage of the removal of their competitors in a process termed serotype replacement ([@B11][@B12][@B13]). An important component of serotype replacement has been the success of "capsule switch" vaccine escape variants ([@B14]). These variants are lineages that were previously associated with a vaccine serotype but have persisted in the postvaccine environment by the introduction of genes for an NVT capsule through homologous recombination ([@B15]). The known ability of the pneumococcus to undergo homologous recombination has also been associated with the acquisition of drug resistance ([@B16], [@B17]) and numerous examples of capsule switch variants ([@B15], [@B18][@B19][@B20]). As a result of this recombination-mediated shuffling of serotype and genotype, when PCVs were introduced, the population already contained potential vaccine escape variants, some of which have subsequently become common and important causes of disease.

The polysaccharide capsule is known to influence multiple aspects of pneumococcal biology. Serotypes vary in their nasopharyngeal carriage rates ([@B21]), and their propensity to cause IPD was usually expressed as the "invasive potential" in order to account for the various exposures to different serotypes ([@B22][@B23][@B24]). Moreover, these properties have been linked to basic biochemical features of the capsule: those capsules with fewer carbons in the repeat unit of the polysaccharide tend to be thicker and exhibit a more negative surface charge ([@B25]) and are associated with a longer duration of carriage and a higher carriage prevalence---an outcome that may be linked to enhanced resistance to opsonophagocytic killing ([@B21]). Those serotypes more associated with virulence meanwhile, tend to have smaller capsules and shorter durations of carriage ([@B21], [@B22], [@B24]).

Despite the importance of both recombination and capsule to pneumococcal biology, whether serotypes vary in their recombination rates in nature and what drives it have not been extensively studied. Genomic studies have shown that different pneumococcal lineages plainly vary in the amount that recombination has contributed to their diversification ([@B20], [@B26]) but have not linked this to the different serotypes associated with each lineage. These studies have also suggested that lineages that completely lack capsule may have a higher relative rate of recombination, suggesting that the capsule can impede the uptake of DNA ([@B26]). Support for this comes from the observation that mechanisms such as biofilm formation and downregulation of capsule biosynthesis have been reported to facilitate DNA uptake and chromosomal integration *in vitro* ([@B27]). This finding suggested that the polysaccharide capsule may inhibit genetic exchange in encapsulated isolates either physically or structurally ([@B28]).

There are hence potentially antagonistic roles for serotype in recombination. A larger capsule is associated with a higher prevalence and longer duration of carriage, therefore offering more opportunities to undergo recombination, but conversely, experimental and observational data suggest that the absence of capsule increases transformation and recombination ([@B26], [@B27]). As yet, there has been no attempt to quantify the association between serotype properties, such as capsule size and carriage duration, and the amount of recombination that those serotypes experience. Understanding this is important because as noted, recombination is crucial to the response of pneumococci to medical interventions ([@B19]), and if serotypes vary in recombination in a predictable fashion, we might be able to predict those that are a higher risk of developing drug resistance or vaccine escape.

In the present study, we used whole genomes of 439 pneumococcal isolates collected in Malawi, a low-income country in sub-Saharan Africa with high pneumococcal carriage rates ([@B29]) and which contains a wide range of serotypes, including serotypes with very low prevalence or that are absent in industrialized countries such as serotype 1 and 5 ([@B18]). We quantified the extent to which recombination has contributed to the history of serotype-specific lineages and combined this with data on carriage duration, invasive potential, carriage prevalence, and capsule size to quantitatively investigate the association. Our results demonstrate significant associations between the recombination rate and frequency with the carriage duration, invasive potential, and size of the outer cell wall polysaccharide capsule in pneumococcal isolates.

RESULTS {#h1}
=======

We sequenced the genomes of 439 *Streptococcus pneumoniae* clinical isolates collected from the Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi (southeastern Africa), between 2002 and 2010. The set of samples comprised 364 invasive isolates and 75 carriage isolates and representatives of 48 distinct serotypes. The most common serotypes were serotype 1 with 83 isolates (52 isolates from blood, 28 isolates from cerebral spinal fluid \[CSF\], and 3 isolates from carriers), serogroup 6 with 46 isolates (25 isolates from blood, 11 isolates from CSF, and 10 isolates from carriers), serotype 5 with 25 isolates (17 isolates from blood, 6 isolates from CSF, and 2 isolates from carriers), and other serotypes (285 isolates; 126 isolates from blood, 99 isolates from CSF, and 60 isolates from carriers) (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material). Whole-genome sequencing was done using the HiSeq platform (Illumina, CA, USA) as described in Materials and Methods. The raw sequence reads had an average length of 72.23 bp (95% confidence interval \[95% CI\], 70.58 to 73.87 bp), average read quality of 33.48 (95% CI, 33.22 to 33.75), and average insert size of 263.30 kb (95% CI, 263.3 to 270.10 kb) per genome ([Fig. S1](#figS1){ref-type="supplementary-material"}). Consensus *de novo* sequence assemblies were generated ([@B30], [@B31]) with an average of 66.43 contigs (95% CI, 63.65 to 69.22) and an average chromosome size of 2.09 Mb (95% CI, 2.09 to 2.10 Mb) and average contig size of 37.31 kb (95% CI, 35.91 to 38.72 kb) per genome. The phylogeny of all the isolates was constructed using a 0.79-Mb multiple-sequence alignment of 852 concatenated core genes containing 51,389 single nucleotide polymorphisms (SNPs) ([@B32]). For the analysis of serotype-specific evolution of lineages identified as described below, SNPs were called against reference genomes ([Table S2](#tabS2){ref-type="supplementary-material"}).

Population structure. {#s1.1}
---------------------

Analysis of the population using BAPS ([@B33], [@B34]) identified 14 primary sequence clusters (SCs) ([Fig. 1](#fig1){ref-type="fig"}). Of these 14 SCs, SC1 to SC13 were monophyletic clades. The remaining SC, SC14, contained sequences that could not be assigned to a monophyletic SC, and the streptococci in this polyphyletic SC are a diverse group of rare lineages, the grouping of which does not necessarily reflect common evolutionary history, and hence, we undertake no further analysis of this group. Most SCs contained isolates with a single serotype and multiple closely related sequence types (STs) as determined by multilocus sequence typing (MLST) ([Fig. 1](#fig1){ref-type="fig"}; see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material). In some cases, SCs contained multiple serotypes separated by long branches. A notable example is SC9, which consisted of clearly distinct subclades of serotype 6A and 35B ([Fig. 1](#fig1){ref-type="fig"}), which we split into two subclades 6A-SC9 and 35B-SC9 for the serotype-specific analyses. The subclade with serotype 35B in SC9 contained additional serotypes with the same ST that were extremely closely related at the whole-genome level ([Fig. 1](#fig1){ref-type="fig"}), which suggests that this subclade was a single lineage of serotype 35B that recently acquired other capsule types.

![Population structure of *S. pneumoniae* strains from carriers and patients with invasive disease**.** The phylogeny was constructed using a 0.79-Mb multiple-sequence alignment with 51,389 SNPs from 852 universally conserved (core) genes present in single copies. The 14 sequence clusters (SCs) identified by BAPS are labeled on the edge of the phylogeny. Clades corresponding to the 13 different monophyletic SCs (SC1 to SC13) are shown in different colors, while clades for all the strains in the polyphyletic clade (SC14) comprising of the "unclustered" sequences are not colored. The outermost ring around the phylogeny shows whether a serotype is a vaccine type (VT) included in the PCV13 pneumococcal vaccine formulation (black) or nonvaccine type (NVT) not included (white). Phylogeny was rooted using an outgroup method on a branch containing nontypeable (NT) pneumococci, which are genetically distinct from all pneumococcal strains.](mbo0051630060001){#fig1}

Variation in recombination among serotypes. {#s1.2}
-------------------------------------------

Pneumococci are known to undergo homologous recombination, and all SCs containing capsule switch variants reflect a history of homologous recombination events. To determine the specific recombination events responsible for these changes, as well as those that could have occurred elsewhere in the genome, we used Gubbins ([@B35]), which identifies regions with an atypically high density of SNPs using a sliding window approach ([Fig. 2a](#fig2){ref-type="fig"} and [b](#fig2){ref-type="fig"}; see [Fig. S3a](#figS3){ref-type="supplementary-material"} to [S3o](#figS3){ref-type="supplementary-material"} in the supplemental material). We distinguish between two separate recombination parameters. The relative recombination rate (μ~*r*/*m*~) is the ratio of the numbers of SNPs introduced by recombination to the number introduced by mutation. It hence measures the total amount of diversity accumulated by a lineage. In contrast, the recombination frequency (μ~re~) is defined as the average number of recombination events inferred per isolate, regardless of how much variation they have introduced. Hence, a large amount of recombination with closely related strains could lead to a high μ~re~ but a low μ~*r*/*m*~. Furthermore, higher presence of shared ancestral recombination events acquired through clonal descent than strain-specific events introduced independently may lead to a high μ~re~. The averages of both these parameters were calculated for each SC. While SC1 and SC2 both contained isolates with a single serotype (serotype 1 and 5, respectively), in the case of SCs containing more than one serotype, the statistics for each were calculated independently ([Table 1](#tab1){ref-type="table"}). Separate estimates were obtained for the two distinct 6A clades in SC3 and SC9, which we refer to as 6A-SC3 and 6A-SC9, respectively, on the basis of the predominant STs in each.

![Recombination inferred by Gubbins. Recombination events mapped onto internal nodes (red blocks) and terminal branches (blue blocks) are illustrated for a typical low-recombination serotype (serotype 1 \[SC1\]) (a) and a high-recombination serotype (serotype 6A \[SC3\]) (b). (i) Maximum likelihood phylogenetic trees of the different serotypes. Branches and tips of the phylogeny are colored according to the MLST sequence type (ST). (ii) Schematic representation of the reference *S. pneumoniae* genome showing all the genetic annotations and locations of some well-known genes. (iii) Matrix showing the tracks representing each genome. The locations and distribution of regions, which have acquired exogenous DNA through recombination, are colored depending on the number of strains that contain them. Recombination events in internal branches (red) were present in multiple isolates and were shared through clonal descent rather than independent acquisitions, while those in the terminal branches (blue) were isolate specific and represent independent recent acquisitions. The recombination rate (μ~*r*/*m*~), i.e., mean number of the inferred distinct recombination events per isolate (each shared ancestral recombination event that occurred once and spread in the clone via clonal descent was counted once). The recombination frequency (μ~re~), i.e., the mean number of SNPs introduced through recombination to those introduced through mutation, is shown. A high presence of recent rather than shared recombination events implies high μ~re~.](mbo0051630060002){#fig2}

###### 

Summary statistics for the genetic recombination events identified in each serotype

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Serotype   Sequence\   No. of\     Mean no. of\             Mean recombination to mutation (μ~*r*/*m*~)   Recombination size (bp)   Pherotype[^a^](#ngtab1.1){ref-type="table-fn"}                                  
             cluster\    isolates\   recombination\                                                                                                                                                                   
             (SC)        (*n*)       events/isolate (μ~re~)                                                                                                                                                           
  ---------- ----------- ----------- ------------------------ --------------------------------------------- ------------------------- ------------------------------------------------ -------------- ------- ------- -------
  5          SC1         25          2                        2.82                                          0.29−5.35                 7,642                                            3,877−11,407   100     0       0

  1          SC2         83          0.73                     2.61                                          0.74−4.48                 8,727                                            5,753−11,702   98.78   0       1.22

  6A         SC3         11          8.91                     23.45                                         1.54−45.44                11,579                                           8,872−14,286   0       100     0

  19A        SC4         12          5.58                     11.26                                         4.64−17.89                9,143                                            6,308−11,979   0       0       100

  16F        SC5         9           0.11                     0.44                                          0−1.39                    36,616                                           0              0       0       100

  3          SC6         10          8.1                      9.45                                          0−23.53                   8,020                                            6,201−9,839    0       0       100

  10B        SC7         14          2.07                     4.15                                          0−8.70                    9,855                                            4,805−14,905   76.47   17.65   5.88

  23F        SC8         19          12.26                    12.53                                         7.33−17.72                8,094                                            6,737−9,451    94.74   0       5.26

  35B        SC9         13          20.08                    17.02                                         5.31−28.74                9,022                                            7,987−10,056   100     0       0

  6A         SC9         12          11.92                    12.85                                         4.55−21.15                7,115                                            5,697−8,532    100     0       0

  12F        SC10        19          5.16                     8.17                                          2.38−13.97                7,709                                            6,016−9,401    94.74   0       5.26

  7A/F       SC11        20          6.4                      8.74                                          3.09−14.38                6,924                                            5,547−8,302    95      0       5

  14         SC12        15          4                        13.93                                         4.70−23.16                6,745                                            4,926−8,563    100     0       0

  18B/C      SC13        8           6.67                     3.49                                          0−11.15                   9,469                                            6,215−12,724   83.78   16.22   0

  4          SC13        6           0.75                     1.67                                          0−3.67                    9,208                                            0−20,175       38.75   32.56   28.29
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Proportion of the pneumococcal pherotypes or competence-stimulating peptide (CSP) encoded by the *comC* gene and its variants in each SC. Detailed information about the CSPs is shown in [Fig. S2c](#figS2){ref-type="supplementary-material"} and [S2d](#figS2){ref-type="supplementary-material"} in the supplemental material.

95% CI, 95% confidence interval.

Estimates of μ~*r*/*m*~ ranged from 0.44 to 23.45 with a mean of 8.89 (95% CI, 5.243 to 12.43) ([Table 1](#tab1){ref-type="table"}), and the only estimate less than 1 was found in the 16F lineage SC5. The highest values of μ~*r*/*m*~ were 12.53 for serotypes 23F-SC8, 23.45 for 6A-SC3, 12.85 for 6A-SC9, and 17.02 for 35B-SC9, while serotypes 1-SC2 (μ~*r*/*m*~ = 2.61), 16F-SC5 (μ~*r*/*m*~ = 0.44), 4-SC13 (μ~*r*/*m*~ = 1.67), and 5-SC1 (μ~*r*/*m*~ = 2.82) showed the lowest values ([Table 1](#tab1){ref-type="table"}). The distribution of μ~*r*/*m*~ values deviated from a normal distribution (*P* \< 0.0001) on the basis of three normality tests (see Materials and Methods). In serotypes of the same SC, such as 35B, 6A, and 18B/C in SC4, SC9, and SC13, respectively, the distribution of *r*/*m* ratios per branch were not different with *P* values of 0.7431 and 0.9350, respectively. The average estimated μ~re~ was 6.316 (95% CI, 3.316 to 9.316) and ranged from 0.11 to 20.08. The highest μ~re~ estimates were 12.26 for 23F-SC8, 20.08 for 35B-SC9, 8.91 for 6A-SC3, and 11.92 for 6A-SC9, while serotypes 1-SC2 (μ~re~ = 0.73), 16F-SC5 (μ~re~ = 0.11), 4-SC13 (μ~re~ = 0.75), and 5-SC1 (μ~re~ = 2) showed the lowest μ~re~ values ([Table 1](#tab1){ref-type="table"}). Significant differences (*P* = 0.0005) in the average numbers of recombination events in each serotype were also observed by using the same test (see [Fig. S2b](#figS2){ref-type="supplementary-material"} in the supplemental material). The Kruskal-Wallis test was used because of significant deviations of the distributions of both μ~*r*/*m*~ per branch in each serotype and the average number of recombination events for each serotype from the normal distribution. Interestingly, both distinct lineages with 6A capsule type consistently showed high μ~*r*/*m*~ (23.45 in SC3 and 12.85 in SC9) and μ~re~ (8.91 in SC3 and 11.92 in SC9) despite having a dissimilar genetic backbone. In addition, μ~*r*/*m*~ positively correlated with μ~re~ (*R^2^* = 0.5168; *P* = 0.0025) ([Fig. 3](#fig3){ref-type="fig"}). The pneumococcal pherotypes or competence-stimulating peptides (CSP) encoded by the *comC* gene were diverse and variably distributed in the SCs but showed no obvious association with the recombination parameters ([Table 1](#tab1){ref-type="table"}).

![Relationship between rate and frequency of genetic recombination estimates in different *S. pneumoniae* serotypes. The solid red circles show the observed values, while the solid white circles show the estimated values by the univariate linear regression model. The dashed lines connecting the red circles to the white circles represent the residual, the difference between the observed and predicted values by the model. The gray band surrounding the regression line shows the 95% confidence interval (95% CI) for prediction of each data point in the horizontal axis. The two serotype 6A symbols in the figure originated from distinct clades, SC3 and SC9, as shown in [Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}.](mbo0051630060003){#fig3}

Serotype-specific carriage duration, prevalence, and invasive potential correlate with recombination. {#s1.3}
-----------------------------------------------------------------------------------------------------

Different pneumococcal lineages vary in the extent of recombination that has influenced their genomes ([@B20], [@B26]). Serotypes are known to vary in their duration of carriage and propensity to cause invasive disease per exposure. A longer duration of carriage could offer more opportunities for cocolonization with different strains and possible recombination. We hence tested the association for each serotype between μ~*r*/*m*~ and μ~re~ and previously published serotype-specific estimates of carriage duration ([@B36]), carriage prevalence data from this study, capsule size ([@B21]), and invasive potential (defined as the odds ratio for causing invasive disease to carriage \[IC~OR~\] \[[@B22], [@B37]\]) using univariate linear regression. We observed a positive association between both μ~*r*/*m*~ (*R^2^* = 0.4664; *P* = 0.0071) and μ~re~ (*R^2^* = 0.3393; *P* = 0.0367) with carriage duration ([Fig. 4a](#fig4){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}; see [Fig. S4a](#figS4){ref-type="supplementary-material"} in the supplemental material), but only μ~*r*/*m*~ showed a significant association (*R^2^* = 0.4173; *P* = 0.0093) with carriage prevalence of the serotypes ([Table 2](#tab2){ref-type="table"}; see [Fig. S6a](#figS6){ref-type="supplementary-material"} and [S6b](#figS6){ref-type="supplementary-material"} in the supplemental material). When modeling the relationship between carriage duration and μ~re,~ serotype 35B-SC9 was excluded as an outlier, but its inclusion decreased the *P* value (*R^2^* = 0.2406; *P* = 0.0749). Both μ~*r*/*m*~ (*R^2^* = 0.4549; *P* = 0.0228) and μ~re~ (*R^2^* = 0.7155; *P* = 0.0010) showed negative association with the invasive potential of the studied serotypes ([Fig. 4b](#fig4){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}; [Fig. S4b](#figS4){ref-type="supplementary-material"} and [S4c](#figS4){ref-type="supplementary-material"}). In multivariable regression, the association of carriage duration, prevalence, and invasive potential disappeared ([Table 2](#tab2){ref-type="table"}). Repeated univariate and multivariate analyses using only those serotypes for which all response variables were available found similar results ([Table S3](#tabS3){ref-type="supplementary-material"}). A multivariate regression to account for this removed the significant association with serotype invasive potential, while the association with carriage duration and capsule size remained ([Table 2](#tab2){ref-type="table"}).

![Statistical relationships between recombination rate (μ~*r*/*m*~) and frequency (μ~re~) with carriage duration and serotype invasive potential (IC~OR~). Univariate regression between μ~*r*/*m*~ and carriage duration (a) and μ~re~ and IC~OR~ (invasive to carriage odds ratio) (b). The solid red circles show the observed values, while the solid white circles show the estimated values by the univariate linear regression model. The dashed lines connecting the red circles to the white circles represent the residual, the difference between the observed and predicted values by the model. The gray band surrounding the regression line shows the 95% confidence interval (CI) for prediction of each data point in the horizontal axis. The two serotype 6A symbols in the figure originated from distinct clades, SC3 and SC9, as shown in [Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}.](mbo0051630060004){#fig4}

###### 

Summarized estimates from the univariate, multivariable, and multivariate multiple regression

  -------------------------------------------------------------------------------------------------------------------------------------------
  Response\             Predictor\     Univariate   Multivariable   Multivariate                                                   
  variable              variable                                                                                                   
  --------------------- -------------- ------------ --------------- -------------- --------- -------- -------- -------- ---------- ----------
  Recombination\        Capsule size   0.0205       0.0186          0.3000         −0.0185   0.0242   0.487    0.9044   14.183     0.0296\*
  rate (μ~*r*/*m*~)                                                                                                                

  Carriage duration     0.3336         0.1030       0.0071\*        0.2149         0.3301    0.550    0.9085   14.884   0.0277\*   

  Invasive potential    −0.7930        0.2894       0.0228\*        −0.8847        0.7927    0.327    0.4032   1.0134   0.4611     

  Carriage prevalence   1.0030         0.3287       0.0093\*        0.1081         0.9468    0.915    0.5457   1.8021   0.3062     

                                                                                                                                   

  Recombination\        Capsule size   0.0263       0.0078          0.0095\*       0.0057    0.0081   0.516    0.9044   14.183     0.0296\*
  frequency (μ~re~)                                                                                                                

  Carriage duration     0.1707         0.0718       0.0367\*        0.2595         0.1101    0.078    0.9085   14.884   0.0277\*   

  Invasive potential    −0.6142        0.1291       0.0010\*        −0.4127        0.2645    0.194    0.4032   1.0134   0.4612     

  Carriage prevalence   0.5443         0.3260       0.1189          −0.4967        0.3159    0.191    0.5457   1.8021   0.3062     
  -------------------------------------------------------------------------------------------------------------------------------------------

The asterisks in the *P* value columns indicate significant values.

All test statistics, i.e., Pillai-Bartlett trace criterion, Wilks' lambda, Hotelling-Lawley trace, and Roy's greatest root, were used to summarize the results from the multivariate analysis of variance (MANOVA) of the multivariate multiple regression model. All the tests showed identical *P* values. For illustration, only estimates using the Pillai-Bartlett trace are shown.

Recombination correlates with larger polysaccharide capsules. {#s1.4}
-------------------------------------------------------------

Capsule size has been associated with the factors described above---the serotype-specific duration of carriage and prevalence. The polysaccharide capsule size data for different pneumococcal serotypes, determined by the fluorescein isothiocyanate-labeled dextran (FITC-dextran) assay, were obtained from Weinberger and colleagues ([@B21]). By using univariate regression, we observed positive association between the capsule size and μ~re~ (*R^2^* = 0.5892; *P* = 0.0095), but not μ~*r*/*m*~ (*R^2^* = 0.1186; *P* = 0.300) ([Fig. 5](#fig5){ref-type="fig"}; [Table 2](#tab2){ref-type="table"}). Excluding serotype 35-SC9, which was deemed to be an outlier observation, the linear association between capsule size and μ~*r*/*m*~ increased (*R^2^* = 0.3519; *P* = 0.0544). This was robust to multivariate analysis (*P* = 0.0296). We also did a multivariable regression to account for collinearity among capsule size, duration of carriage, carriage prevalence, and invasive potential and identify the independent contribution of each, which showed no association between μ~*r*/*m*~ and μ~re~ ([Table 2](#tab2){ref-type="table"}; see [](#tabS2){ref-type="supplementary-material"}[Table S3](#tabS3){ref-type="supplementary-material"} in the supplemental material).

![Relationship between frequency of recombination (μ~re~) and polysaccharide capsule size in pneumococcal isolates. Serotype 35-SC9 was excluded from the regression, as it was deemed an outlier observation. The solid red circles show the observed values, while the solid white circles show the estimated values by the univariate linear regression model. The dashed lines connecting the red circles to the white circles representthe residual, the difference between the observed and predicted values by the model. The gray band surrounding the regression line shows the 95% confidence interval (CI) for prediction of each data point in the horizontal axis. The two serotype 6A symbols in the figure originated from distinct clades, SC3 and SC9, as shown in [Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}.](mbo0051630060005){#fig5}

DISCUSSION {#h2}
==========

Recombination is a fundamental process in the evolution and adaptation of many pathogens. It is capable of shuffling existing variation into more fit combinations, and in the case of pneumococcus, it has been an important force in its response to medical interventions like vaccines and antibiotics ([@B19]). Despite the obvious benefits to the pathogen that recombination offers in this regard, the rates with which it occurs vary greatly among pneumococcal lineages and serotypes ([@B26]) for reasons that are obscure. Understanding the factors that contribute to this variation is important as we attempt to limit the potential of pneumococcal evolution to erode the benefits of clinical innovation.

Previous studies have commented on the low presence of recombination in certain serotypes, such as the "highly invasive" serotypes 1 and 7F ([@B20], [@B38], [@B39]). A systematic comparison of capsular types is challenging because some serotypes are comparatively rare or absent from samples taken in industrialized countries, and while it might be possible to combine studies from different sites, it would be important to account for any bias arising from variation in recombination in different regions---for instance, previous work with MLST data found more evidence of recombination in samples from African carriers and speculated that this might be the consequence of a higher carriage rate ([@B40]).

We have used a set of pneumococcal samples that includes an unusually wide range of serotypes with diverse properties, and we found a clear association between serotype and μ~*r*/*m*~ and μ~re~. Because of lack of data in resource-poor settings, we used previously published data on the properties of serotypes, such as capsule size, carriage duration, prevalence, and invasive capacity (all of which vary relatively little among sample sites); we found that all were associated with one recombination parameter or the other recombination parameter or both. In univariate analysis, a negative association with invasive capacity mirrored a positive association of μ~*r*/*m*~ with carriage duration and prevalence---likely reflecting the fact that the majority of highly invasive serotypes are also infrequently carried. However, it should be noted that we did not have specific invasiveness data from pneumococci infecting the Malawi population, and there are few estimates for this quantity from resource-poor settings, so this is an important focus for future work.

We have also found more frequent recombination in serotypes with larger outer cell wall polysaccharide capsules, which shows that despite the potential physical barrier offered by the capsule, the presence of a larger capsule itself does not simply reduce recombination. While this could be considered surprising, it is important to note that serotypes with enlarged capsules are typically carried for longer duration and resist neutrophil phagocytosis ([@B21]) and complement-mediated immune responses ([@B41], [@B42]) than serotypes with smaller capsules. In addition, this may be because some of the serotypes with larger capsules have lower metabolic costs ([@B21]) associated with capsule expression and may have a higher ability to form biofilms which may prevent elimination ([@B27]). This suggests that longer duration of carriage and lower clearance rates by the host's immune system in serotypes with enlarged capsules leads to sustained exposure to cocolonizers (potential donors of exogenous DNA), which has been previously described to facilitate recombination ([@B40]). This in turn results in higher recombination than in serotypes with thinner capsules, which are presented with limited opportunities for recombination due to rapid clearance. The intrinsic recombination rates *in vitro* in the absence of capsule-induced immune clearance may be different than observed in the natural population where various factors such as strain competition and immune responses can directly affect the recombination rate. Hence, the results of *in vitro* studies may be misleading when applied to the nasopharynx. In addition, there was no obvious association between the pneumococcal pherotypes such as CSP1, CSP2, and other variants encoded by the *comC* gene and its allelic variants, which suggests that the observed differences in recombination may not be due to the differences in competence. The evidence presented here certainly strongly suggests that capsule does not prevent recombination in any straightforward fashion. However, while capsule size was associated with a higher frequency of recombination (μ~re~), the association with μ~*r*/*m*~ was not significant in the univariate regression. Nevertheless, the effect of capsule size and carriage duration in a multivariate analysis accounts for the high correlation between the two recombination parameters, i.e., μ~*r*/*m*~ and μ~re~, indicating that these two factors are key contributors to the observed variation. The capsule data used in this study were obtained *in vitro*, and the expressed capsule sizes during carriage and transmission remain unclear and should be investigated in follow-up studies.

The properties of the capsule that we have studied here are also highly correlated (Pearson correlation coefficients are shown in [Fig. S7](#figS7){ref-type="supplementary-material"} in the supplemental material), and accounting for this removed the association ([Table 2](#tab2){ref-type="table"}). As a result, we have not been able to precisely define the underlying causes. A plausible mechanism is that serotypes with larger capsules are more exposed to other cocolonizing strains because they are carried for a longer period and at a higher prevalence. One way to test this would be to use serotype switches as natural experiments and compare μ~*r*/*m*~ and μ~re~ between switched lineages where the two serotypes involved vary in their size. However, this is limited by the fact that serotype switches identified in [Fig. 1](#fig1){ref-type="fig"} and other studies typically involve serotypes that are effective colonizers such as serogroups 6, 15, 18, 19, and 23 ([@B15]). While this means we cannot use the present data set to do the above analysis, we should note that this observation is consistent with the suggestion that more commonly carried types are more likely to undergo recombination with each other.

In conclusion, we have shown that in a set of samples from Malawi containing many different serotypes, there is a linear relationship between μ~re~ and μ~*r*/*m*~ and properties of the capsule. In general, there is evidence that recombination increases with carriage duration and polysaccharide capsule size. We have not been able to pick out the causal roots of this relationship due to the complexity of the relationships between other important properties also associated with capsule, but the observation shows conclusively that all serotypes are not alike and that serotypes differ in how recombination has affected their evolution history, which has been associated with many different responses from drug resistance to vaccine escape. The serotypes observed in settings with a high burden of carriage and disease, such as sub-Saharan Africa, are often different from those found in industrialized nations, and there has been concern that lineages with serotypes targeted by vaccine such as serotypes 1, 5, and 7F that are relatively invasive, with a short duration of carriage and small capsules, might survive a serotype switch ([@B21], [@B22], [@B36]). The results of this study suggest that such concerns may be misplaced.

MATERIALS AND METHODS {#h3}
=====================

Isolate collection and genome sequencing. {#s3.1}
-----------------------------------------

We collected 439 *S. pneumoniae* isolates from the Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) pneumococcal isolate archive in Blantyre, Malawi. The isolates were routinely collected from patients at the Queen Elizabeth Central Hospital, a 1,250-bed referral hospital and the largest hospital located in the Blantyre District in southern Malawi from 2002 to 2011. All isolates were collected before the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in routine childhood immunization programs in Malawi in 2011. Isolates were collected from carriers (*n* = 75) and patients with invasive disease (*n* = 364) from 2002 to 2011 (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material). Isolates were cultured in Todd-Hewitt broth, and genomic DNA was extracted using the Promega Wizard DNA genomic DNA purification kit (Promega, USA). DNA sequencing was done using the Illumina genome analyzer II (Illumina, CA, USA) platform at the Wellcome Trust Sanger Institute. A robust bespoke pipeline ([@B43]) that was composed of the Velvet v1.2.09 De Bruijn graph-based DNA sequence assembler ([@B30]), Velvet Optimizer ([@B31]), SSPACE Basic v2.0 contig-scaffolding software ([@B44]), GapFiller ([@B45]), and SMALT v0.7.4 short-read aligner (<http://sourceforge.net/projects/smalt/>) was used to generate sequence assemblies from the paired-end Illumina sequence reads for the study isolates. Serotypes were identified from the whole-genome sequence data using an *in silico* approach implemented with Perl and BioPerl ([@B46]) as described by Croucher et al. ([@B47]).

Population structure and phylogenetic analysis. {#s3.2}
-----------------------------------------------

Phylogenetic trees were constructed using a 0.79-Mb sequence alignment of 51,389 single nucleotide polymorphisms (SNPs) in 852 concatenated core genes present in single copies (no paralogs). The conserved (core) and nonconserved (accessory) genes were identified using the Roary bacterial genome analysis pipeline ([@B32]). The population structure of the isolates was inferred using the hierBAPS module implemented in BAPS v6.0 ([@B33], [@B34]). Maximum likelihood phylogenies of the concatenated core gene alignments for all the study isolates and serotype-specific isolates in the inferred sequence clusters (SCs) from BAPS were constructed using RAxML v7.0.4 ([@B48]). We used a generalized time reversible (GTR) ([@B49]) model with gamma (Υ) heterogeneity across nucleotide sites and 100 bootstrap replicates. The tree was rooted with an outgroup clade of nontypeable (NT) isolates, which form a distinct clade from other pneumococci ([@B50]). Phylogenetic trees and associated metadata, namely, sequence types (STs), serotypes, and inclusion of the sample's serotype in the PCV13 vaccine formulation, were overlaid on the phylogenies and visualized in iToL ([@B51]) and BioPython scripts ([@B52]).

Recombination detection and phylogeny construction. {#s3.3}
---------------------------------------------------

Phylogenies for specific serotypes were generated for downstream phylogenetic analysis through mapping paired-end short sequence reads against different published reference whole-genome sequences (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material) for different pneumococcal serotypes using SMALT v0.7.4. The output binary alignment map (BAM) files were realigned using the Genome Analysis Tool Kit (GATK) v3.3.0 ([@B53]). The locations of recombination events in each chromosome in the alignments were detected using Gubbins v1.1.1 ([@B35]). The serotype-specific phylogenies with recombination removed were constructed using RAxML v7.0.4 ([@B48]) as above and rooted in the middle of the branch, separating the two most divergent isolates. Visualization of the phylogenies was done as described in "Population structure and phylogenetic analysis" above.

Carriage duration, serotype invasive potential, and capsule size. {#s3.4}
-----------------------------------------------------------------

We used previously published data from Kilifi in Kenya, data on carriage duration of pneumococcal serotypes in the human nasopharynx from Abdullahi and colleagues ([@B36]) and data on serotype invasive potential (odds ratio for IPD to carriage \[IC~OR~\]) from Brueggemann and colleagues ([@B22]). Additional data for serotype 5 invasive potential were obtained from Smith and colleagues ([@B37]). The polysaccharide capsule sizes for the serotypes were obtained from Weinberger and colleagues ([@B21]) where the degree of encapsulation was determined by measuring the zone of exclusion using the fluorescein isothiocyanate-labeled dextran (FITC-dextran) assay. The specific methods used to obtain the data sets are described in the respective publications. We excluded serotypes with estimated IC~OR~ values of 0 ([@B22]) to prevent overfitting as a consequence of the smaller number of isolates used from invasive disease sample collection. Genomic data on the relative recombination rate and frequency of pneumococcal lineages and prevalence of serotypes in carriage were obtained from Malawi (this study).

Statistical analysis. {#s3.5}
---------------------

We used univariate, multivariable, and multivariate multiple regression to examine the association between known properties of serotypes and the relative recombination rate (μ~*r*/*m*~) and frequency (μ~re~). The univariate regression model were separately formulated as *Y~i~* = β~0~ + β~1~*x~i~* + ε~i~ for each dependent variable *Y~i~*(μ~*r*/*m*~ and μ~re~) against each independent variable *x~i~* where *i* designates the polysaccharide capsule size, carriage duration, serotype invasive potential, and carriage prevalence. The intercept and regression coefficient for the independent variables are represented by β~0~ and β~1~, respectively, while ε~i~ represents the residuals. We formulated the multivariable model similarly but included multiple independent variables to account for collinearity between them as *Y~i~* = β~0~ + β~1~*x~i~* + β~2~*x*~i~ + β~3~*x*~i~ + β~4~*x~i~* + ε~i~, where β~0~ represents the intercept and the terms β~1~, β~2,~ β~3,~ and β~4~ are the regression coefficients for each independent variable (*x~i~*) where *i* is polysaccharide capsule size, carriage duration, serotype invasive potential and carriage prevalence. We also modeled the relationship between both dependent variables (μ~*r*/*m*~ and μ~re~) and the independent variables in the multivariable regression this time with a multivariate multipl e regression model. The multivariate model was formulated as *Y*~n*x*m~ = *X*~n*x*(*p*+1)~β~(*p*+1)*x*m~ + ε~n*x*m~, where *n* designates each serotype and lineage combination as follows 1-SC2, 5-SC1, 6A-SC3,  ..., and 4-SC13 (Table 1). The *m* in the matrix *Y*~n*x*m~ takes values 1 and 2 that designate dependent variables μ~*r*/*m*~ and μ~re~, respectively. The model matrix is the term *X*~n*x*(*p*+1)~ and consists of *p*+1 regressors where *p* represents polysaccharide capsule size, carriage duration, serotype invasive potential, and carriage prevalence of serotypes. The first column in the model matrix *X*~n*x*(*p*+1)~ consists of 1*s*, which represents the regression constants. The matrix of regression coefficients for all the independent variables in *X*~n*x*(*p*+1)~ is represented by parameter β. The residual term in the model is represented by the matrix ε~n*x*m~. For comparison with the multivariable and multivariate analyses, we repeated the univariate analyses with the same sample size.

We calculated the pairwise Pearson correlation coefficients for independent and response variables and plotted them using the ggplot2 package. The regression analysis, normality tests, namely, D'Agostino and Pearson, Shapiro-Wilk, and Kolmogorov-Smirnov tests, Kruskal-Wallis and analysis of variance (ANOVA) tests and summary statistics, such as means and ranges, were calculated using R v3.1.2 (R Core Team, 2014) and GraphPad Prism v6.0 (GraphPad Software, Inc., CA, USA).

SUPPLEMENTAL MATERIAL {#sm1}
=====================

###### 

Assembly statistics of the pneumococcal study isolates. (a) Length of the assembled genomes; (b) mean number of contigs per genome; (c) mean contig length; (d) *N*~50~ assembly statistic; (e) mean number of contigs in *N*~50~; (f) mean read length; (g) percentage of total mapped sequence reads; (h) percentage of the total bases mapped. Download
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Figure S1, EPS file, 2.1 MB
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Characteristics of the genetic recombination events identified in the pneumococcal isolates. (a) Distribution of recombination rates on branches of the serotype-specific phylogenies; (b) sizes of recombination blocks identified in the genomes of each pneumococcal serotype; (c) distribution of the competence-stimulating peptide (CSP) variants across the sequence clusters (SCs); (d) protein multiple-sequence alignment of the CSPs encoded by the *comC* gene. Other variants of the *comC* gene in additional to the CSP1 and CSP2 were arbitrarily named CPS3 to CSP10. Download
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Figure S2, TIF file, 1 MB
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Recombination inferred by Gubbins. Pneumococcal serotypes 5-SC1 (a), 2-SC1 (b), 6A-SC3 (c), 19A-SC4 (d), 16F-SC5 (e), 3-SC6 (f), 10B-SC7 (g), 23F-SC8 (h), 6A-SC9 (i), 35B-SC9 (j), 12F-SC10 (k), 7AF-SC11 (l), 14-SC12 (m), 4-SC13 (n), and 18 A/F-SC13 (o). (i) Maximum likelihood phylogenetic trees of the different serotypes. Branches and tips of the phylogeny are colored according to the MLST sequence type (ST). (ii) Schematic representation of the reference *S. pneumoniae* genome showing all the genetic annotations and locations of some well-known genes. (iii) Matrix showing the tracks representing each genome. The locations and distribution of regions, which have acquired exogenous DNA through recombination, are colored depending on the number of strains that contain them. Recombination events in internal branches (red) were present in multiple isolates and were shared through clonal descent, rather than independent acquisitions, while those in the terminal branches (blue) were isolate specific and represent independent recent acquisitions. The recombination rate (μ~*r*/*m*~), i.e., mean number of the inferred distinct recombination events per isolate (each shared ancestral recombination event that occurred once and spread in the clone via clonal descent was counted once) and the recombination frequency (μ~re~), i.e., the mean number of SNPs introduced through recombination to those introduced through mutation are shown. A high presence of recent recombination events rather than shared recombination events implies a high μ~re~. Download
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Figure S3, TIF file, 1.6 MB
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Relationships between recombination rate (μ~*r*/*m*~) and frequency (μ~re~) with carriage duration and invasive potential in pneumococcal isolates. Univariate regression between μ~re~ and carriage duration (a) and μ~*r*/*m*~ and IC~OR~ (invasive to carriage odds ratio) (b). The solid red circles show the observed values, while the solid white circles show the estimated values by the univariate linear regression model. The dashed lines connecting the red circles to the white circles represent the residual, the difference between the observed and predicted values by the model. The gray band surrounding the regression line shows the 95% confidence interval (CI) for prediction of each data point in the horizontal axis. The two serotype 6A symbols in the figure originated from distinct clades, SC3 and SC9, as shown in [Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}. Download
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Figure S4, EPS file, 1.9 MB
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Recombination dynamics and capsule polysaccharide capsule sizes in pneumococcal serotypes. (a) Recombination frequency (μ~re~) and capsule size. Serotype 35-SC9 (light pink) was excluded, as it was deemed an outlier. (b) Recombination rate (μ~*r*/*m*~) and capsule sizes. The solid red circles show the observed values, while the solid white circles show the estimated values by the univariate linear regression model. The dashed lines connecting the red circles to the white circles represent the residual, the difference between the observed and predicted values by the model. The gray band surrounding the regression line shows the 95% confidence interval (CI) for prediction of each data point in the horizontal axis. The two serotype 6A symbols in the figure originated from distinct clades, SC3 and SC9, as shown in [Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}. Download
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Figure S5, EPS file, 1 MB

###### 

Relationship between frequency (μ~re~) of recombination and carriage prevalence in pneumococcal isolates. (a) μ~*r*/*m*~ and carriage prevalence; (b) μ~re~ and carriage prevalence. The solid red circles show the observed values, while the solid white circles show the estimated values by the univariate linear regression model. The dashed lines connecting the red circles to the white circles represent the residual, the difference between the observed and predicted values by the model. The gray band surrounding the regression line shows the 95% confidence interval (CI) for prediction of each data point in the horizontal axis. The two serotype 6A symbols in the figure originated from distinct clades, SC3 and SC9, as shown in [Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}. Download
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Figure S6, EPS file, 1.9 MB
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Composite Pearson correlation matrix derived for the variables. The independent (predictor) variables, namely, carriage duration and capsule size, are indicated by two asterisks, while the different dependent (response) variables, namely, recombination rate (μ~*r*/*m*~), recombination frequency (μ~re~), serotype invasive potential (IC~OR~), and prevalence in carriage and invasive disease, do not have an asterisk. Download
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Figure S7, EPS file, 1.2 MB
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Streptococcus pneumoniae isolates used in this study.
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Table S1, DOCX file, 0.2 MB
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Reference pneumococcal whole-genome sequences used in this study.

###### 

Table S2, DOCX file, 0.1 MB
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Summarized estimates from the univariate and multivariable regression. Only serotypes with all the different independent variables present, i.e., capsule size, carriage duration, invasive potential, and carriage prevalence were used.
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Table S3, DOCX file, 0.1 MB
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